SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.
Veno-venous extracorporeal membrane oxygenation support in covid-19 respiratory distress syndrome: Initial experience / Loforte A.; Dal Checco E.; Gliozzi G.; Benedetto M.; Cavalli G.G.; Mariani C.; Piccone G.; Agulli M.; Pacini D.; Baiocchi M.. - In: ASAIO JOURNAL. - ISSN 1058-2916. - STAMPA. - 66:7(2020), pp. 734-738. [10.1097/MAT.0000000000001198]
Veno-venous extracorporeal membrane oxygenation support in covid-19 respiratory distress syndrome: Initial experience
Loforte A.;Gliozzi G.;Cavalli G. G.;Mariani C.;Piccone G.;Agulli M.;Pacini D.;
2020
Abstract
SARS-CoV-2 may cause severe respiratory failure due to massive alveolar damage. Currently, no adequate curative therapy for Coronavirus Disease 2019 (COVID-19) disease exists. By considering overall impact of COVID-19 pandemic outbreak, an increased need of extracorporeal membrane oxygenation (ECMO) support becomes evident. We report on our preliminary institutional experience with COVID-19 patients receiving venovenous ECMO support. ASAIO Journal 2020; 66:734-738.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
